CY1108165T1 - ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ - Google Patents

ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ

Info

Publication number
CY1108165T1
CY1108165T1 CY20081100682T CY081100682T CY1108165T1 CY 1108165 T1 CY1108165 T1 CY 1108165T1 CY 20081100682 T CY20081100682 T CY 20081100682T CY 081100682 T CY081100682 T CY 081100682T CY 1108165 T1 CY1108165 T1 CY 1108165T1
Authority
CY
Cyprus
Prior art keywords
decoy
treatment
stat
skin
atophic
Prior art date
Application number
CY20081100682T
Other languages
Greek (el)
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg, Inc. filed Critical Anges Mg, Inc.
Publication of CY1108165T1 publication Critical patent/CY1108165T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20081100682T 2001-02-20 2008-06-30 ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ CY1108165T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
EP02711351A EP1362600B1 (en) 2001-02-20 2002-02-06 TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS

Publications (1)

Publication Number Publication Date
CY1108165T1 true CY1108165T1 (el) 2014-02-12

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100682T CY1108165T1 (el) 2001-02-20 2008-06-30 ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ

Country Status (11)

Country Link
US (2) US9012417B2 (cg-RX-API-DMAC7.html)
EP (2) EP1362600B1 (cg-RX-API-DMAC7.html)
JP (2) JP3778357B2 (cg-RX-API-DMAC7.html)
AT (1) ATE390938T1 (cg-RX-API-DMAC7.html)
CY (1) CY1108165T1 (cg-RX-API-DMAC7.html)
DE (1) DE60225899T2 (cg-RX-API-DMAC7.html)
DK (1) DK1362600T3 (cg-RX-API-DMAC7.html)
ES (1) ES2307733T3 (cg-RX-API-DMAC7.html)
PT (1) PT1362600E (cg-RX-API-DMAC7.html)
TW (1) TWI308492B (cg-RX-API-DMAC7.html)
WO (1) WO2002066070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
TWI308492B (cg-RX-API-DMAC7.html) * 2001-02-20 2009-04-11 Anges Mg Inc
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
JP2007512845A (ja) * 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
WO2006034433A2 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US8067384B2 (en) 2004-10-22 2011-11-29 Anges Mg, Inc. Chimera (double) decoy
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
EP1892293A4 (en) * 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
US20100035793A1 (en) * 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
WO2009119836A1 (ja) * 2008-03-28 2009-10-01 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
ES2285712T3 (es) 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
JPH11507245A (ja) * 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
CA2294988C (en) * 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (ja) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
WO2001057204A1 (en) * 2000-02-02 2001-08-09 Yasufumi Kaneda Virus envelope vector for gene transfer
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
TWI308492B (cg-RX-API-DMAC7.html) 2001-02-20 2009-04-11 Anges Mg Inc
WO2003063911A1 (en) * 2002-02-01 2003-08-07 Anges Mg, Inc. Decoy-containing pharmaceutical compositions and method of using the same
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
PT1362600E (pt) 2008-07-09
EP1690544B1 (en) 2017-09-13
DK1362600T3 (da) 2008-07-28
TWI308492B (cg-RX-API-DMAC7.html) 2009-04-11
JP2009102428A (ja) 2009-05-14
JPWO2002066070A1 (ja) 2004-06-17
US9012417B2 (en) 2015-04-21
EP1690544A3 (en) 2012-03-07
EP1362600A4 (en) 2005-09-21
EP1690544A2 (en) 2006-08-16
DE60225899D1 (de) 2008-05-15
ES2307733T3 (es) 2008-12-01
WO2002066070A1 (fr) 2002-08-29
US20090105183A1 (en) 2009-04-23
EP1362600A1 (en) 2003-11-19
ATE390938T1 (de) 2008-04-15
JP3778357B2 (ja) 2006-05-24
DE60225899T2 (de) 2009-04-09
EP1362600B1 (en) 2008-04-02
US20040162251A1 (en) 2004-08-19
JP4987022B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
ES2191192T3 (es) Tienopirimidinas.
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
DE60124285D1 (de) Beschichtete medizinische geräte
EP1181947A3 (en) Spinal cord stimulation leads
CO5160266A1 (es) Nuevos agentes antibacterianos de isoxazolinona
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
EP2144608A4 (en) SUN PROTECTION COMPOSITIONS AND METHODS
ATE232396T1 (de) Oxydiertes thymosin beta 4
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
WO2004012652A3 (en) Treatment of multiple sclerosis with brain targeted anti oxidant compounds
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy